Cellular Immunotherapy for Septic Shock

NCT03369275 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

114

Enrollment

OTHER

Sponsor class

Conditions

Septic Shock
Sepsis
Pathologic Processes
Shock
Infection
Systemic Inflammatory Response Syndrome
Inflammation

Interventions

BIOLOGICAL: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
OTHER: Placebo

Sponsor

Ottawa Hospital Research Institute

Collaborators

[object Object]
[object Object]
[object Object]